Published online before print September 12, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||





,
,

,¶

,¶
Departments of
* Microbiology and Immunology and
Pharmacology,
Center for Substance Abuse Research, and the
¶ Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, Pennsylvania; and
Laboratory of Molecular Immunoregulation, Division of Basic Sciences, National Cancer Institute-Frederick Cancer Research and Development Center, Maryland
1 Correspondence: Department of Microbiology and Immunology, Temple University School of Medicine, 3400 N. Broad Street, Philadelphia, PA 19140. E-mail address: rogerst{at}temple.edu
The opiates are well-established immunomodulatory factors, and recent evidence suggests that µ- and
-opioid receptor ligands alter chemokine-driven chemotactic responses through the process of heterologous desensitization. In the present report, we sought to examine the capacity of µ- and
-opioids to modulate the function of chemokine receptors CCR5 and CXCR4, the two major human immunodeficiency virus (HIV) coreceptors. We found that the chemotactic responses to the CCR1/5 ligand CCL5/regulated on activation, normal T expressed and secreted, but not the CXCR4 ligand stromal cell-derived factor-1
/CXCL12 were inhibited following opioid pretreatment. Studies were performed with primary monocytes and Chinese hamster ovary cells transfected with CCR5 and the µ-opioid receptor to determine whether cross-desensitization of CCR5 was a result of receptor internalization. Using radiolabeled-binding analysis, flow cytometry, and confocal microscopy, we found that the heterologous desensitization of CCR5 was not associated with a significant degree of receptor internalization. Despite this, we found that the cross-desensitization of CCR5 by opioids was associated with a decrease in susceptibility to R5 but not X4 strains of HIV-1. Our findings are consistent with the notion that impairment of the normal signaling activity of CCR5 inhibits HIV-1 coreceptor function. These results have significant implications for our understanding of the effect of opioids on the regulation of leukocyte trafficking in inflammatory disease states and the process of coreceptor-dependent HIV-1 infection. The interference with HIV-1 uptake by heterologous desensitization of CCR5 suggests that HIV-1 interaction with this receptor is not passive but involves a signal transduction process.
Key Words: chemokines neuroimmunology cell trafficking AIDS
This article has been cited by other articles:
![]() |
R. Sengupta, S. Burbassi, S. Shimizu, S. Cappello, R. B. Vallee, J. B. Rubin, and O. Meucci Morphine Increases Brain Levels of Ferritin Heavy Chain Leading to Inhibition of CXCR4-Mediated Survival Signaling in Neurons J. Neurosci., February 25, 2009; 29(8): 2534 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, S. D. Douglas, J.-S. Peng, D.-J. Zhou, Q. Wan, and W.-Z. Ho An in Vitro Model of Morphine Withdrawal Manifests the Enhancing Effect on Human Immunodeficiency Virus Infection of Human T Lymphocytes through the Induction of Substance P Am. J. Pathol., November 1, 2006; 169(5): 1663 - 1670. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Zhang, D. Yang, H. Dong, Q. Chen, D. I. Dimitrova, T. J. Rogers, M. Sitkovsky, and J. J. Oppenheim Adenosine A2a receptors induce heterologous desensitization of chemokine receptors Blood, July 1, 2006; 108(1): 38 - 44. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Adler and T. J. Rogers Are chemokines the third major system in the brain? J. Leukoc. Biol., December 1, 2005; 78(6): 1204 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Huttenrauch, B. Pollok-Kopp, and M. Oppermann G Protein-coupled Receptor Kinases Promote Phosphorylation and {beta}-Arrestin-mediated Internalization of CCR5 Homo- and Hetero-oligomers J. Biol. Chem., November 11, 2005; 280(45): 37503 - 37515. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Tegeder and G. Geisslinger Opioids As Modulators of Cell Death and Survival--Unraveling Mechanisms and Revealing New Indications Pharmacol. Rev., September 1, 2004; 56(3): 351 - 369. [Abstract] [Full Text] [PDF] |
||||